AMD 3100. JM 3100, SDZ SID 791.
D000818:Animals; D019380:Anti-HIV Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D001596:Benzylamines; D017322:Clinical Trials, Phase II as Topic; D000080027:Cyclams; D015507:Drugs, Investigational / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects*; D015498:HIV-2 / Q000187:drug effects*; D006571:Heterocyclic Compounds / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007279:Injections, Subcutaneous; D051379:Mice; D016513:Mice, SCID; D008970:Molecular Weight; D011485:Protein Binding; D051381:Rats
D019380:Anti-HIV Agents; D001596:Benzylamines; D000080027:Cyclams; D015507:Drugs, Investigational; D006571:Heterocyclic Compounds; C088327:plerixafor